Spero Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Spero Therapeutics CEO'su Esther Rajavelu, Aug2023 tarihinde atandı, in görev süresi 1.5 yıldır. şirketin hisselerinin 0.063% doğrudan sahiptir ve bu hisselerin değeri € 29.05K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.6 yıl ve 10.8 yıldır.

Anahtar bilgiler

Esther Rajavelu

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.5yrs
CEO sahipliği	0.06%
Yönetim ortalama görev süresi	2.6yrs
Yönetim Kurulu ortalama görev süresi	10.8yrs

Son yönetim güncellemeleri

Recent updates

CEO

Esther Rajavelu (45 yo)

1.5yrs

Görev süresi

Ms. Esther P. Rajavelu serves as Chief Financial Officer and Chief Business Officer at Spero Therapeutics Inc. since August 1, 2023 and also serves as its Treasurer since November 2023 and serves as its Pr...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ankit Mahadevia	Co-Founder & Director	12.1yrs	US$2.39m	0.43% € 197.2k
Timothy Keutzer	Chief Operating Officer	2yrs	US$1.44m	0.12% € 57.1k
Esther Rajavelu	Interim President	1.5yrs	Veri yok	0.063% € 29.0k
James Brady	Chief Human Resource Officer	3.3yrs	Veri yok	Veri yok

2.6yrs

Ortalama Görev Süresi

45yo

Ortalama Yaş

Deneyimli Yönetim: 2HA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ankit Mahadevia	Co-Founder & Director	11.4yrs	US$2.39m	0.43% € 197.2k
Frank Thomas	Independent Chairman	7.6yrs	US$88.83k	0.028% € 12.7k
Milind Deshpande	Independent Director	11.1yrs	US$105.70k	0.058% € 26.6k
Eric Gordon	Scientific Advisors	10.8yrs	Veri yok	Veri yok
George Drusano	Clinical Advisor	10.8yrs	Veri yok	Veri yok
Steven Gilman	Scientific Advisor	no data	Veri yok	Veri yok
Patrick V. J. Vink	Lead Independent Director	9.4yrs	US$93.19k	0.028% € 12.7k
Gordon Archer	Clinical Advisor	10.8yrs	Veri yok	Veri yok
David Livermore	Scientific Advisor	no data	Veri yok	Veri yok
Paul Miller	Scientific Advisor	no data	Veri yok	Veri yok
Paul Ambrose	Clinical Advisor	10.8yrs	Veri yok	Veri yok
Cynthia Smith	Independent Director	5.9yrs	US$73.20k	0.028% € 12.7k

10.8yrs

Ortalama Görev Süresi

62.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 2HA 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.8 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/02/06 21:18
Gün Sonu Hisse Fiyatı	2025/02/06 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Spero Therapeutics, Inc. 9 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Esther Lannie Hong	Berenberg
Jason Matthew Gerberry	BofA Global Research
Joshua Schimmer	Evercore ISI

Spero Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Spero Therapeutics, Inc. Announces Executive and Board Changes

Spero Therapeutics, Inc., Annual General Meeting, May 29, 2024

Co-Founder & Chairman of the Board recently sold €81k worth of stock

Spero Therapeutics Appoints Esther Rajavelu as Chief Business Officer

Spero Therapeutics, Inc., Annual General Meeting, Oct 05, 2023

Spero Therapeutics, Inc. Announces Chief Financial Officer Changes

Recent updates

Spero Therapeutics, Inc. Announces Executive and Board Changes

Third quarter 2024 earnings released: US$0.32 loss per share (vs US$0.061 loss in 3Q 2023)

Investor sentiment improves as stock rises 17%

Spero Therapeutics, Inc. Announces SPR720 Phase 2a Interim Results

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.33 loss per share (vs US$0.23 loss in 2Q 2023)

Spero Therapeutics, Inc. to Report Q2, 2024 Results on Aug 05, 2024

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.25 loss in 1Q 2023)

Spero Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

Spero Therapeutics, Inc., Annual General Meeting, May 29, 2024

New major risk - Revenue and earnings growth

Spero Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings released: EPS: US$0.43 (vs US$1.24 loss in FY 2022)

Spero Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024

New minor risk - Profitability

Co-Founder & Chairman of the Board recently sold €81k worth of stock

Spero Therapeutics, Inc. Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Forecast to breakeven in 2026

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.061 loss per share (vs US$0.33 loss in 3Q 2022)

Spero Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Spero Therapeutics Appoints Esther Rajavelu as Chief Business Officer

Spero Therapeutics, Inc., Annual General Meeting, Oct 05, 2023

New major risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.23 loss per share (vs US$0.87 loss in 2Q 2022)

Spero Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Spero Therapeutics, Inc. Announces Chief Financial Officer Changes

First quarter 2023 earnings released: US$0.25 loss per share (vs US$1.01 loss in 1Q 2022)

Spero Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$1.24 loss per share (vs US$2.91 loss in FY 2021)

Spero Therapeutics, Inc. Appoints Timothy Keutzer as Chief Operating Officer, Effective as of February 1, 2023

Insufficient new directors

Third quarter 2022 earnings released: US$0.33 loss per share (vs US$0.70 loss in 3Q 2021)

Insufficient new directors

Spero Therapeutics, Inc. announced that it has received $8.999973 million in funding from GSK plc

Spero Therapeutics to Present Data at IDWeek 2022

Spero Therapeutics, Inc. announced that it expects to receive $8.999973 million in funding from GSK plc

Spero Therapeutics Announces Appointment of Kamal Hamed as Chief Medical Officer

Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration

Second quarter 2022 earnings released: US$0.87 loss per share (vs US$0.63 loss in 2Q 2021)

Spero Therapeutics, Inc., Annual General Meeting, Sep 15, 2022

The Gross Law Firm Notifies Shareholders of Spero Therapeutics, Inc. of A Class Action Lawsuit

Spero Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for Its New Drug Application

Pomerantz Law Firm Announces the Filing of Class Action Lawsuit Against Spero Therapeutics, Inc

First quarter 2022 earnings released: US$1.01 loss per share (vs US$0.66 loss in 1Q 2021)

Spero Therapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

No longer forecast to breakeven

Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline

Insufficient new directors

Full year 2021 earnings released: US$2.91 loss per share (vs US$3.52 loss in FY 2020)

Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206

Spero Therapeutics Receives Up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients

Spero Therapeutics, Inc. Announces Lifting of FDA Clinical Trial Hold on SPR720

Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem Hbr for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.70 loss per share (vs US$0.86 loss in 3Q 2020)

Insufficient new directors

Forecast to breakeven in 2023

Second quarter 2021 earnings released: US$0.63 loss per share (vs US$0.85 loss in 2Q 2020)

Spero Therapeutics, Inc. announced that it has received $39.994552 million in funding from Pfizer Inc.

Spero Therapeutics, Inc. Announces the Initiation of Bronchoalveolar Lavage and Renal Impairment Clinical Trials of Spr206

Spero Therapeutics, Inc. Wins Funding of $2.09 Million, with the Potential for Up to an Additional $21.3 Million over 5 Years, from the National Institute of Allergy and Infectious Diseases

First quarter 2021 earnings released: US$0.66 loss per share (vs US$1.22 loss in 1Q 2020)

Full year 2020 earnings released: US$3.52 loss per share (vs US$3.36 loss in FY 2019)

Revenue misses expectations

New 90-day high: €19.00

Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial